• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-10POS filed by Neovasc Inc.

    4/11/23 9:08:04 AM ET
    $NVCN
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $NVCN alert in real time by email
    F-10POS 1 tm239185d4_f10pos.htm F-10POS

     

    As filed with the Securities and Exchange Commission on April 11, 2023

    Registration No. 333-255293

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM F-10

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    NEOVASC INC.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Canada 3841 Not Applicable
    (Jurisdiction of Incorporation) (Primary Standard Industrial
    Classification Code Number)
    (I.R.S. Employer
    Identification No.)

     

    Suite 5138 – 13562 Maycrest Way

    Richmond, British Columbia, Canada V6V 2J7

    (604) 270-4344

    (Address and telephone number of Registrant’s principal executive offices)

     

    CT Corporation System

    28 Liberty Street

    New York, New York 10011

    (212) 894-8940

    (Name, Address and Telephone Number of Agent for Service)

     

     

     

    Copy to:

    Michael J. Hong, Esq.

    Skadden, Arps, Slate, Meagher & Flom LLP

    222 Bay Street

    Toronto, Ontario M5K 1J5

    (416) 777-4700

     

    Joseph A. Garcia, Esq.

    Kyle Misewich, Esq.

    Blakes, Cassels & Graydon LLP

    595 Burrard Street, Suite 2600

    Vancouver, British Columbia, Canada  V7X 1L3

    (604) 631-3300

     

     

     

    Approximate date of commencement of proposed sale to public: Not applicable. Removal from registration of securities that were not sold pursuant to this registration statement.

     

    Canada

    Province of British Columbia

    (Principal Jurisdiction Regulating this Offering)

     

     

     

    It is proposed that this filing shall become effective (check appropriate box):

     

    A. x Upon filing with the Commission pursuant to Rule 467(a) (if in connection with an offering being made contemporaneously in the United States and Canada).

     

    B. ¨ At some future date (check the appropriate box below).

     

      1. ☐ Pursuant to Rule 467(b) on                      (date) at                      (time) (designate a time not sooner than seven calendar days after filing).

     

      2. ☐ Pursuant to Rule 467(b) on                      (date) at                      (time) (designate a time not sooner than seven calendar days after filing) because the securities regulatory authority in the review jurisdiction has issued a receipt or notification of clearance on                      (date).

     

      3. ☐ Pursuant to Rule 467(b) as soon as practicable after notification of the Commission by the registrant or the Canadian securities regulatory authority of the review jurisdiction that a receipt or notification of clearance has been issued with respect hereto.

     

      4. ☐ After the filing of the next amendment to this form (if preliminary material is being filed).

     

    If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to the home jurisdiction’s shelf prospectus offering procedures, check the following box.  ☐

     

     

     

     

     

     

    EXPLANATORY NOTE – DEREGISTRATION OF UNSOLD SECURITIES

     

    This Post-Effective Amendment No. 1 (this “Post-Effective Amendment”) is being filed by Neovasc Inc. (the “Registrant”) to withdraw from registration all of the unsold securities registered under the Registration Statement on Form F-10 (Registration No. 333-255293), filed by the Registrant with the U.S. Securities and Exchange Commission on April 16, 2021, as amended by Amendment No. 1 on May 4, 2021 (the “Registration Statement”), registering the sale by the Registrant from time to time of such indeterminate number of common shares, preferred shares, debt securities, warrants, units and subscription receipts of the Registrant as shall have an aggregate offering price not to exceed US$150,000,000.

     

    Effective on April 11, 2023, Shockwave Medical, Inc. (“Shockwave”) acquired all of the issued and outstanding common shares of the Registrant pursuant to an arrangement agreement dated January 16, 2023, by and between the Registrant and Shockwave, in accordance with a court-approved plan of arrangement (the “Arrangement”) under the Canada Business Corporations Act.

     

    As a result of the Arrangement, the Registrant has terminated any and all offerings of its securities pursuant to the Registration Statement. In accordance with an undertaking contained in the Registration Statement to remove from registration by means of a post-effective amendment any of the securities registered under the Registration Statement that remain unsold at the termination of the offering, the Registrant hereby removes from registration all of its securities registered but unsold under the Registration Statement as of the date hereof.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-10 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement on Form F-10 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Richmond, British Columbia, Canada, on April 11, 2023.

     

      NEOVASC INC.
         
         
      By: /s/ Chris Clark
        Name: Chris Clark
        Title: Chief Financial Officer

     

     

     

     

    AUTHORIZED REPRESENTATIVE

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned certifies that it is the duly authorized United States representative of Neovasc Inc. and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on behalf of it by the undersigned, thereunto duly authorized, in the City of Richmond, British Columbia, Canada on April 11, 2023.

     

      NEOVASC (US) INC.
      (Authorized U.S. Representative)
         
         
      By: /s/ Chris Clark
        Name: Chris Clark
        Title: Director

     

     

     

    Get the next $NVCN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVCN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVCN
    Financials

    Live finance-specific insights

    See more
    • Volato Announces Changes to Board Composition

      Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024 Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement. The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger

      4/24/24 6:00:00 AM ET
      $BSX
      $SOAR
      $NVCN
      Medical/Dental Instruments
      Health Care
      Transportation Services
      Consumer Discretionary
    • Neovasc Announces Third Quarter Financial Results and Provides Corporate Update

      VANCOUVER and MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") ((NASDAQ, TSX:NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third quarter of 2021. Accelerating acceptance of Reducer in the UK and French markets, with France the largest volume market in the quarter. Continued enrollment in the COSIRA II pivotal trial, with enrollment expected to be complete in the first half of 2024 and initial data readout in the second half of 2024. In July, 2022, the Company re

      11/10/22 4:05:00 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • Neovasc to Report Third Quarter Financial Results on November 10, 2022

      VANCOUVER and MINNEAPOLIS, Oct. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ ,  TSX : NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm ET on November 10, 2022. Interested parties may access the conference call by dialing (800) 458-4121 or (856) 344-9290 (International) and reference Conference ID 7304031. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc we

      10/27/22 9:00:00 AM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    SEC Filings

    See more
    • SEC Form EFFECT filed by Neovasc Inc.

      EFFECT - NEOVASC INC (0001399708) (Filer)

      8/3/23 12:15:07 AM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 15F-12B filed by Neovasc Inc.

      15F-12B - NEOVASC INC (0001399708) (Filer)

      4/24/23 4:15:05 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Neovasc Inc.

      6-K - NEOVASC INC (0001399708) (Filer)

      4/12/23 1:10:18 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SVB Leerink resumed coverage on Neovasc with a new price target

      SVB Leerink resumed coverage of Neovasc with a rating of Buy and set a new price target of $2.00

      3/14/21 8:09:11 AM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Volato Announces Changes to Board Composition

      Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024 Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement. The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger

      4/24/24 6:00:00 AM ET
      $BSX
      $SOAR
      $NVCN
      Medical/Dental Instruments
      Health Care
      Transportation Services
      Consumer Discretionary
    • Neovasc Shareholders Approve Acquisition by Shockwave Medical

      Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ:NVCN) (TSX:NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting").The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareholders o

      3/6/23 6:00:00 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • Neovasc Shareholders Approve Acquisition by Shockwave Medical

      VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareh

      3/6/23 5:37:44 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Neovasc Inc. (Amendment)

      SC 13G/A - NEOVASC INC (0001399708) (Subject)

      2/14/22 3:25:50 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13D filed

      SC 13D - NEOVASC INC (0001399708) (Subject)

      2/25/21 3:14:38 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G filed

      SC 13G - NEOVASC INC (0001399708) (Subject)

      2/19/21 4:24:07 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care